Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze AUPH stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate AUPH investment potential.

What is AUPH stock price today?

Get real-time AUPH stock price, historical data, and price charts on Financhill. Track AUPH performance with our advanced analysis tools.

Is AUPH a good investment?

Evaluate AUPH investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy AUPH stock?

To buy AUPH stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of AUPH?

View detailed market capitalization data and company valuation metrics for AUPH on our comprehensive analysis page.

What is the P/E ratio of AUPH?

Use our fundamental analysis tools to view AUPH P/E ratio and compare valuation metrics with industry peers.

What are AUPH earnings?

View AUPH earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Aurinia Pharmaceuticals, Inc. 10K Form

Buy

AUPH
Aurinia Pharmaceuticals, Inc.

Last Price:

$15.04

Seasonality Move:

0.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly
2023-11-02	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly
2023-08-03	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly
2023-05-04	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly
2022-11-03	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly
2022-08-04	10Q	AUPH/Aurinia Pharmaceuticals, Inc. Quarterly

Receive AUPH News And Ratings

See the #1 stock for the next 7 days that we like better than AUPH

AUPH Financial Statistics

Sales & Book Value

Annual Sales:	$283.1M
Cash Flow:	$44.5M
Price / Cash Flow:	14.47
Annual Sales:	$4.39
Price / Book:	3.21

Profitability

EPS (TTM):	2.07710
Net Income (TTM):	$287.2M
Gross Margin:	$250.4M
Return on Equity:	71.44%
Return on Assets:	50.28%

Aurinia Pharmaceuticals, Inc. Earnings Forecast

Key Aurinia Pharmaceuticals, Inc. Financial Ratios

The Gross Profit Margin over the past 28 years for AUPH is 88.46%.
The Selling, General & Administrative Expenses for AUPH have been equal to 35.96% of Gross Profit Margin.
The Research & Development expenses have been 11.48% of Revenue.
The Interest Expense is 1.51% of Operating Income.
The Net Earning history of AUPH is 101.47% of Total Revenues.
Per Share Earnings over the last 28 years have been positive in 13 years.

Aurinia Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	AUPH
CUSIP:	05156V
Website:	auriniapharma.com

Debt

Debt-to-Equity Ratio:	0.13
Current Ratio:	5.25
Quick Ratio:	4.69

Price-to-Earnings

Trailing P/E Ratio:	6.83
Forward P/E Ratio:	16.95

AUPH Technical Analysis vs Fundamental Analysis

Buy

Aurinia Pharmaceuticals, Inc. (AUPH) is a Buy

Is Aurinia Pharmaceuticals, Inc. a Buy or a Sell?

Aurinia Pharmaceuticals, Inc. stock is rated a Buy

The current Aurinia Pharmaceuticals, Inc. [AUPH] share price is $14.15. The Score for AUPH is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.